Showing 6631-6640 of 7027 results for "".
- Study: Most Skin-Cancer Apps Unreliablehttps://practicaldermatology.com/news/20130123-study_most_skin-cancer_apps_unreliable/2459630/The University of Pittsburgh studied four smartphone apps that evaluate melanoma by analyzing images submitted by the users. One app works by having a board-certified dermatologist look at the photos, while the other three apps analyze the images by computer algorithm. The best-performing of the com
- Provectus Pharmaceuticals to Present on PV-10 at AACRhttps://practicaldermatology.com/news/20130123-provectus_pharmaceuticals_to_present_on_pv-10_at_aacr/2459631/Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination o
- Free Skin Cancer Screenings January 26 in Southeasthttps://practicaldermatology.com/news/20130115-free_skin_cancer_screenings_january_26_in_southeast/2459636/Gulf Coast Dermatology will offer free full-body skin cancer screenings on Saturday, January 26 from 9 a.m. to noon at several of their locations. The screenings are provided by appointment only and are for new patients. Appointments for the
- CeraVe Sun Care Partners with Olympic Swimmer Rebecca Sonihttps://practicaldermatology.com/news/20130115-cerave_sun_care_partners_with_olympic_swimmer_rebecca_soni/2459637/CeraVe Sun Care, a new line by Valeant Pharmaceuticals North America LLC, will partner with swimmer Rebecca Soni, six-time US Olympic medalist and World Record holder in the 100- and 200-meter breaststroke, as the face of the brand in 2013. The CeraVe
- Modernizing Medicine Completes $12 Million Capital Raisehttps://practicaldermatology.com/news/20130111-modernizing_medicine_completes_12_million_capital_raise/2459639/Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, completed a $12 million capital raise, with a combination of equity capital and a senior bank debt facility. The company plans to use the funding to, among other things, acc
- Women's Dermatologic Society Event January 15https://practicaldermatology.com/news/20130111-womens_dermatologic_society_event_january_15/2459640/The Women's Dermatologic Society, sponsored by Glytone, will hold a “Look Before You Leap” Media Day 2013 on January 15, a series of desk-side appointments with the editorial community focusing on the pitfalls, complications, problems, and myths surrounding skin care and dermatology topics. Founded
- Tana Poppino to Be Celtic Complexion Sponsorhttps://practicaldermatology.com/news/20130110-tana_poppino_to_be_celtic_complexion_sponsor/2459641/Florida-based skin care company Celtic Complexion announced a sponsorship agreement with professional rodeo barrel racer Tana Poppino. Ms. Poppino, who lives in Big Cabin, OK, is a full-time contestant on the professional rodeo circuit. S
- DemaSculpt Offers Free Sampleshttps://practicaldermatology.com/news/20130110-demasculpt_offers_free_samples/2459642/To celebrate the launch of their post-injection, anti-bruising cream PostFill, DemaSculpt will include a free sample (a $17.95 value) with each DemaSculpt order received before January 31. In addition, all orders over $198 ship free in Januar
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM